Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.
Identifieur interne : 000238 ( Main/Exploration ); précédent : 000237; suivant : 000239Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.
Auteurs : Nancy Broos [Pays-Bas] ; Eugène P. Van Puijenbroek ; Kees Van GrootheestSource :
- Drug safety [ 1179-1942 ] ; 2010.
Descripteurs français
- KwdFr :
- Aidants (MeSH), Enfant d'âge préscolaire (MeSH), Enquêtes et questionnaires (MeSH), Facteurs temps (MeSH), Femelle (MeSH), Fièvre (étiologie), Grippe humaine (prévention et contrôle), Humains (MeSH), Immunisation (statistiques et données numériques), Internet (MeSH), Mâle (MeSH), Nourrisson (MeSH), Parents (MeSH), Pays-Bas (épidémiologie), Programmes nationaux de santé (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Systèmes de signalement des effets indésirables des médicaments (MeSH), Vaccination de masse (MeSH), Vaccins antigrippaux (effets indésirables).
- MESH :
- effets indésirables : Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A.
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Immunisation.
- épidémiologie : Pays-Bas.
- étiologie : Fièvre.
- Aidants, Enfant d'âge préscolaire, Enquêtes et questionnaires, Facteurs temps, Femelle, Humains, Internet, Mâle, Nourrisson, Parents, Programmes nationaux de santé, Systèmes de signalement des effets indésirables des médicaments, Vaccination de masse.
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
- Adverse Drug Reaction Reporting Systems (MeSH), Caregivers (MeSH), Child, Preschool (MeSH), Female (MeSH), Fever (etiology), Humans (MeSH), Immunization (statistics & numerical data), Infant (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (adverse effects), Influenza, Human (prevention & control), Internet (MeSH), Male (MeSH), Mass Vaccination (MeSH), National Health Programs (MeSH), Netherlands (epidemiology), Parents (MeSH), Surveys and Questionnaires (MeSH), Time Factors (MeSH).
- MESH :
- chemical , adverse effects : Influenza Vaccines.
- geographic , epidemiology : Netherlands.
- etiology : Fever.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human.
- statistics & numerical data : Immunization.
- Adverse Drug Reaction Reporting Systems, Caregivers, Child, Preschool, Female, Humans, Infant, Internet, Male, Mass Vaccination, National Health Programs, Parents, Surveys and Questionnaires, Time Factors.
Abstract
BACKGROUND
In November 2009, all children in the Netherlands from 6 months up to 4 years of age were indicated to receive the Influenza A (H1N1) vaccine. Fever is a common adverse event following immunization in children. Pandemrix®, an inactivated, split-virus influenza A (H1N1) vaccine, was used for this age group. A clinical study mentioned in the Summary of Product Characteristics of Pandemrix® found an increased reactogenicity after the second dose in comparison with the first dose, particularly in the rate of fever. In the Netherlands, this adverse reaction was a point of concern for the parents or caregivers of these children.
OBJECTIVE
To investigate the course and height of fever following the first and second dose of Pandemrix® in children aged from 6 months up to 4 years. The secondary aim was to evaluate the use of an online survey during a vaccination campaign.
DESIGN
Survey-based descriptive study.
SETTING
Adverse drug reaction reporting database of the Netherlands Pharmacovigilance Centre (Lareb).
PARTICIPANTS
Parents or caregivers (n = 839) of vaccinated children who reported fever to Lareb following the first immunization with Pandemrix®. Questionnaires were sent by email to parents or caregivers of eligible children following the first and second doses of Pandremix®.
MAIN OUTCOME MEASURES
Time between vaccination and the occurrence of fever, the maximum measured temperature, the occurrence of other adverse events after first and second vaccination, the decision to get the second vaccination and the social implication of the fever in terms of absence from work, nursery or school, and hospitalization.
RESULTS
Following the first vaccination against Influenza A (H1N1), the height of the fever was between 39.0 and 40.0°C in 359/639 (56.2%) of the children. In most of these children (235/639 [36.8%]), the onset of fever was between 6 and 12 hours following vaccination. 450/639 (70.4%) children recovered within 2 days. Of the 539 responders to the second questionnaire, 380 (70.5%) received the second vaccination against Influenza A (H1N1) and 213 (56.1%) of these children experienced fever again. The height of the fever was significantly lower (t-test; p = 0.001) and the duration was significantly shorter (Pearson's Chi-square; p = 0.002) in comparison with the first vaccination. The height of the fever after the first vaccination was associated with the decision to receive the second vaccination (t-test; p = 0.000). In the studied group, 342 (53.5%) parents or caregivers needed to stay home from work and 405 (63.4%) children stayed home from nursery or school due to fever following the first vaccination.
CONCLUSIONS
The results of this study can be used in future vaccination campaigns to be able to inform people in an evidence-based manner about the risks and benefits of the vaccine and to avoid unnecessary concern and negative media attention. This could contribute to improved immunization levels. A web-based survey is demonstrated to be a useful tool to quickly gather information about a current safety concern and consequently inform the public to support an ongoing vaccination campaign.
DOI: 10.2165/11539280-000000000-00000
PubMed: 21077701
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.</title><author><name sortKey="Broos, Nancy" sort="Broos, Nancy" uniqKey="Broos N" first="Nancy" last="Broos">Nancy Broos</name><affiliation wicri:level="1"><nlm:affiliation>Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands. nancybroos@hotmail.com</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch</wicri:regionArea><wicri:noRegion>'s-Hertogenbosch</wicri:noRegion></affiliation></author><author><name sortKey="Van Puijenbroek, Eugene P" sort="Van Puijenbroek, Eugene P" uniqKey="Van Puijenbroek E" first="Eugène P" last="Van Puijenbroek">Eugène P. Van Puijenbroek</name></author><author><name sortKey="Van Grootheest, Kees" sort="Van Grootheest, Kees" uniqKey="Van Grootheest K" first="Kees" last="Van Grootheest">Kees Van Grootheest</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:21077701</idno><idno type="pmid">21077701</idno><idno type="doi">10.2165/11539280-000000000-00000</idno><idno type="wicri:Area/Main/Corpus">000223</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000223</idno><idno type="wicri:Area/Main/Curation">000223</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000223</idno><idno type="wicri:Area/Main/Exploration">000223</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.</title><author><name sortKey="Broos, Nancy" sort="Broos, Nancy" uniqKey="Broos N" first="Nancy" last="Broos">Nancy Broos</name><affiliation wicri:level="1"><nlm:affiliation>Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands. nancybroos@hotmail.com</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch</wicri:regionArea><wicri:noRegion>'s-Hertogenbosch</wicri:noRegion></affiliation></author><author><name sortKey="Van Puijenbroek, Eugene P" sort="Van Puijenbroek, Eugene P" uniqKey="Van Puijenbroek E" first="Eugène P" last="Van Puijenbroek">Eugène P. Van Puijenbroek</name></author><author><name sortKey="Van Grootheest, Kees" sort="Van Grootheest, Kees" uniqKey="Van Grootheest K" first="Kees" last="Van Grootheest">Kees Van Grootheest</name></author></analytic><series><title level="j">Drug safety</title><idno type="eISSN">1179-1942</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems (MeSH)</term><term>Caregivers (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>Fever (etiology)</term><term>Humans (MeSH)</term><term>Immunization (statistics & numerical data)</term><term>Infant (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (prevention & control)</term><term>Internet (MeSH)</term><term>Male (MeSH)</term><term>Mass Vaccination (MeSH)</term><term>National Health Programs (MeSH)</term><term>Netherlands (epidemiology)</term><term>Parents (MeSH)</term><term>Surveys and Questionnaires (MeSH)</term><term>Time Factors (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Aidants (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Facteurs temps (MeSH)</term><term>Femelle (MeSH)</term><term>Fièvre (étiologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Immunisation (statistiques et données numériques)</term><term>Internet (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Parents (MeSH)</term><term>Pays-Bas (épidémiologie)</term><term>Programmes nationaux de santé (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Systèmes de signalement des effets indésirables des médicaments (MeSH)</term><term>Vaccination de masse (MeSH)</term><term>Vaccins antigrippaux (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Fever</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Immunization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Immunisation</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Pays-Bas</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Fièvre</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term><term>Caregivers</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Internet</term><term>Male</term><term>Mass Vaccination</term><term>National Health Programs</term><term>Parents</term><term>Surveys and Questionnaires</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Aidants</term><term>Enfant d'âge préscolaire</term><term>Enquêtes et questionnaires</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Internet</term><term>Mâle</term><term>Nourrisson</term><term>Parents</term><term>Programmes nationaux de santé</term><term>Systèmes de signalement des effets indésirables des médicaments</term><term>Vaccination de masse</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>In November 2009, all children in the Netherlands from 6 months up to 4 years of age were indicated to receive the Influenza A (H1N1) vaccine. Fever is a common adverse event following immunization in children. Pandemrix®, an inactivated, split-virus influenza A (H1N1) vaccine, was used for this age group. A clinical study mentioned in the Summary of Product Characteristics of Pandemrix® found an increased reactogenicity after the second dose in comparison with the first dose, particularly in the rate of fever. In the Netherlands, this adverse reaction was a point of concern for the parents or caregivers of these children.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To investigate the course and height of fever following the first and second dose of Pandemrix® in children aged from 6 months up to 4 years. The secondary aim was to evaluate the use of an online survey during a vaccination campaign.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>Survey-based descriptive study.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING</b></p><p>Adverse drug reaction reporting database of the Netherlands Pharmacovigilance Centre (Lareb).</p></div><div type="abstract" xml:lang="en"><p><b>PARTICIPANTS</b></p><p>Parents or caregivers (n = 839) of vaccinated children who reported fever to Lareb following the first immunization with Pandemrix®. Questionnaires were sent by email to parents or caregivers of eligible children following the first and second doses of Pandremix®.</p></div><div type="abstract" xml:lang="en"><p><b>MAIN OUTCOME MEASURES</b></p><p>Time between vaccination and the occurrence of fever, the maximum measured temperature, the occurrence of other adverse events after first and second vaccination, the decision to get the second vaccination and the social implication of the fever in terms of absence from work, nursery or school, and hospitalization.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Following the first vaccination against Influenza A (H1N1), the height of the fever was between 39.0 and 40.0°C in 359/639 (56.2%) of the children. In most of these children (235/639 [36.8%]), the onset of fever was between 6 and 12 hours following vaccination. 450/639 (70.4%) children recovered within 2 days. Of the 539 responders to the second questionnaire, 380 (70.5%) received the second vaccination against Influenza A (H1N1) and 213 (56.1%) of these children experienced fever again. The height of the fever was significantly lower (t-test; p = 0.001) and the duration was significantly shorter (Pearson's Chi-square; p = 0.002) in comparison with the first vaccination. The height of the fever after the first vaccination was associated with the decision to receive the second vaccination (t-test; p = 0.000). In the studied group, 342 (53.5%) parents or caregivers needed to stay home from work and 405 (63.4%) children stayed home from nursery or school due to fever following the first vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The results of this study can be used in future vaccination campaigns to be able to inform people in an evidence-based manner about the risks and benefits of the vaccine and to avoid unnecessary concern and negative media attention. This could contribute to improved immunization levels. A web-based survey is demonstrated to be a useful tool to quickly gather information about a current safety concern and consequently inform the public to support an ongoing vaccination campaign.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21077701</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.</ArticleTitle><Pagination><MedlinePgn>1109-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2165/11539280-000000000-00000</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In November 2009, all children in the Netherlands from 6 months up to 4 years of age were indicated to receive the Influenza A (H1N1) vaccine. Fever is a common adverse event following immunization in children. Pandemrix®, an inactivated, split-virus influenza A (H1N1) vaccine, was used for this age group. A clinical study mentioned in the Summary of Product Characteristics of Pandemrix® found an increased reactogenicity after the second dose in comparison with the first dose, particularly in the rate of fever. In the Netherlands, this adverse reaction was a point of concern for the parents or caregivers of these children.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the course and height of fever following the first and second dose of Pandemrix® in children aged from 6 months up to 4 years. The secondary aim was to evaluate the use of an online survey during a vaccination campaign.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Survey-based descriptive study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Adverse drug reaction reporting database of the Netherlands Pharmacovigilance Centre (Lareb).</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Parents or caregivers (n = 839) of vaccinated children who reported fever to Lareb following the first immunization with Pandemrix®. Questionnaires were sent by email to parents or caregivers of eligible children following the first and second doses of Pandremix®.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Time between vaccination and the occurrence of fever, the maximum measured temperature, the occurrence of other adverse events after first and second vaccination, the decision to get the second vaccination and the social implication of the fever in terms of absence from work, nursery or school, and hospitalization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Following the first vaccination against Influenza A (H1N1), the height of the fever was between 39.0 and 40.0°C in 359/639 (56.2%) of the children. In most of these children (235/639 [36.8%]), the onset of fever was between 6 and 12 hours following vaccination. 450/639 (70.4%) children recovered within 2 days. Of the 539 responders to the second questionnaire, 380 (70.5%) received the second vaccination against Influenza A (H1N1) and 213 (56.1%) of these children experienced fever again. The height of the fever was significantly lower (t-test; p = 0.001) and the duration was significantly shorter (Pearson's Chi-square; p = 0.002) in comparison with the first vaccination. The height of the fever after the first vaccination was associated with the decision to receive the second vaccination (t-test; p = 0.000). In the studied group, 342 (53.5%) parents or caregivers needed to stay home from work and 405 (63.4%) children stayed home from nursery or school due to fever following the first vaccination.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of this study can be used in future vaccination campaigns to be able to inform people in an evidence-based manner about the risks and benefits of the vaccine and to avoid unnecessary concern and negative media attention. This could contribute to improved immunization levels. A web-based survey is demonstrated to be a useful tool to quickly gather information about a current safety concern and consequently inform the public to support an ongoing vaccination campaign.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Broos</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands. nancybroos@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Puijenbroek</LastName><ForeName>Eugène P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>van Grootheest</LastName><ForeName>Kees</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="N">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009313" MajorTopicYN="N">National Health Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="N">Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21077701</ArticleId><ArticleId IdType="pii">6</ArticleId><ArticleId IdType="doi">10.2165/11539280-000000000-00000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Infect Dis. 2004 Aug 1;39(3):389-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15307007</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1977 Dec;136 Suppl:S731-41</Citation><ArticleIdList><ArticleId IdType="pubmed">606798</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2004 Jan 26;22(5-6):551-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14741143</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2010 Dec 1;33(12):1097-108</Citation><ArticleIdList><ArticleId IdType="pubmed">21077700</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2009;32(4):309-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19388722</ArticleId></ArticleIdList></Reference><Reference><Citation>Fam Pract. 1991 Mar;8(1):32-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2044869</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2001 Jun;107(6):1241-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11389237</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country></list><tree><noCountry><name sortKey="Van Grootheest, Kees" sort="Van Grootheest, Kees" uniqKey="Van Grootheest K" first="Kees" last="Van Grootheest">Kees Van Grootheest</name><name sortKey="Van Puijenbroek, Eugene P" sort="Van Puijenbroek, Eugene P" uniqKey="Van Puijenbroek E" first="Eugène P" last="Van Puijenbroek">Eugène P. Van Puijenbroek</name></noCountry><country name="Pays-Bas"><noRegion><name sortKey="Broos, Nancy" sort="Broos, Nancy" uniqKey="Broos N" first="Nancy" last="Broos">Nancy Broos</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000238 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000238 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippePaysBasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21077701
|texte= Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21077701" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippePaysBasV1
| This area was generated with Dilib version V0.6.35. |  |